Dianthus Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	132.33	15.37	133.43	59.93	66.85	60.13	51.57	4.54
Short-Term Investments	41.39	60.13	45.28	90.68	80.66	84.23	0	0
Cash & Cash Equivalents	173.72	75.49	178.71	150.62	147.51	144.35	51.57	4.54
Cash Growth	130.12%	-57.76%	18.65%	2.11%	2.19%	179.93%	1035.09%	-
Receivables	0.48	5.64	0	0	0	0	0	6.25
Other Current Assets	3.26	0.91	1.99	0.91	2.33	0.97	0.94	0.04
Total Current Assets	177.45	82.03	180.69	151.53	149.84	145.32	52.5	10.83
Property, Plant & Equipment	0.8	0.96	7.46	8.31	9.89	10.21	1.96	0.51
Other Long-Term Assets	1.15	0.12	1.78	1.78	1.78	1.78	0	0
Total Long-Term Assets	1.95	1.08	9.24	10.09	11.67	11.99	1.96	0.51
Total Assets	179.41	83.11	189.93	161.62	161.51	157.31	54.46	11.34
Accounts Payable	2.61	1.17	3.04	3.76	2.81	3.49	0.17	1.67
Deferred Revenue	0.84	0.89	0	0	0	0	0	0
Current Debt	0.42	0.35	0	0	0	0	0	0
Other Current Liabilities	5.77	5.82	7.82	7.67	11.3	6.93	3.98	0.63
Total Current Liabilities	9.63	8.23	10.86	11.43	14.12	10.42	4.14	2.3
Long-Term Debt	0.17	0.44	0	0	0	0	0	0
Other Long-Term Liabilities	0.74	0.79	6.4	6.28	6.21	1.25	0	17.92
Total Long-Term Liabilities	0.9	1.23	6.4	6.28	6.21	1.25	0	17.92
Total Liabilities	10.54	9.45	17.26	17.71	20.32	11.67	4.14	20.22
Total Debt	0.59	0.79	0	0	0	0	0	0
Debt Growth	-25.76%	-	-	-	-	-	-	-
Retained Earnings	-89.42	-45.87	-325.57	-254.43	-179.5	-102.73	-45.21	-9.72
Comprehensive Income	0.05	-0.16	-0.03	-0.02	0.01	-0.01	0	0
Shareholders' Equity	168.87	-44.37	172.67	143.91	141.19	145.65	-42.12	-8.87
Net Cash / Debt	173.13	74.7	178.71	150.62	147.51	144.35	51.57	4.54
Net Cash / Debt Growth	131.76%	-58.20%	18.65%	2.11%	2.19%	179.93%	1035.09%	-
Net Cash Per Share	33.60	85.45	52.04	54.87	63.76	125.59	444.32	486.51
Working Capital	167.82	73.81	169.83	140.1	135.73	134.9	48.36	8.53
Book Value Per Share	32.77	-50.75	50.28	52.42	61.03	126.72	-362.91	-950.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).